11 November 2016 — “Today after years of negotiation, Pfizer finally announced that it was reducing the price of its pneumococcal conjugate vaccine, Prevenar 13, (PCV13) to 3.10 per dose (US$ 9.30 per child for all three doses) for humanitarian organisations working in emergency settings. This is definitely a step in the right direction and will help to protect millions of vulnerable children around the world and in MSF projects. The details of Pfizer’s offer are still to be determined, so we look forward to hearing more as they solidify their commitment. We now hope that Pfizer will extend its efforts to developing countries by offering a lower price to all governments which still can’t afford to protect their children against pneumonia."
- Jason Cone, MSF USA Executive director
